Final results of the ENACT Phase II clinical trial of the drug, NA-1 (TAT-NR2B9c) for reducing Stroke damage, from NoNo...
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).
Ionis Pharmaceuticals announced that GSK has initiated two randomized, double-blind, placebo-controlled Phase III studies evaluating the safety and efficacy of GSK 3228836 (bepirovirsen) (formerly IONIS-HBVRx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B infection (CHB)
A single-arm, open-label, two-stage multicenter, phase II study. Patients will be pre-screened for ALK positive status. Treatment with LDK378 at...
AbbVie announced that the FDA has granted approval of Mavyret (glecaprevir/pibrentasvir) to shorten the once-daily treatment duration from 12 to...
Despite surgical and medical innovation have reduced mortality rates in cardiac surgery, the disease severity and operative procedural complexity have...
The purpose of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus insulin glargine once-daily on glycaemic control after 30 weeks of treatment in insulin-naïve subjects with type 2 diabetes.
ViiV Healthcare presented at the 22nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 &...
Janssen Biotech announced the submission of a supplemental New Drug Application (sNDA) to the FDA seeking to expand the indication...
Merck and Pfizer announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab in a...